A genetically-defined trial can be designed correctly and still stall. The protocol names the right molecular subtype, the endpoints are sound, and the therapeu...
Continue reading
Precision medicine clinical trials are designed by some of the most capable scientists in drug development. The biomarker hypotheses are well-reasoned, the endp...
Continue reading
On July 20, 2026, Mayo Clinic reported peer-reviewed evidence that decentralization changes who takes part in clinical research. In a study published in JAMA Ne...
Continue reading
Most people with inflammatory bowel disease do not carry one broken gene. They carry risk spread across many genes and regulatory regions at once, which is why ...
Continue reading
On 20 July 2026, The New York Times reported that the genetic risk tools entering clinical use do not perform equally well across populations. Polygenic risk sc...
Continue reading
Most people accumulate cancer-associated blood mutations as they age, and quietly, without ever developing cancer. A growing body of evidence now links those mu...
Continue reading
For decades, the dominant framework for understanding neurodegenerative disease has centered on inherited risk genes. A growing body of single-cell genomics res...
Continue reading
The NIH’s All of Us Research Program has become the world’s largest integrated genomic and electronic health record database. Its June 30 data release includes ...
Continue reading
The C9orf72 hexanucleotide repeat expansion is the most common genetic cause of both ALS and frontotemporal dementia (FTD). Carriers face roughly a 50% chance o...
Continue reading
When a gene therapy sponsor pauses a clinical program, the operational machinery responds within hours. The medical monitor convenes a safety review. Regulatory...
Continue reading